NCT01397877 2023-09-06
ENDOPIK
ARCAGY/ GINECO GROUP
Phase 2 Completed
Clinical Trials
14 trialsNCT01285466 2020-12-09
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Novartis
Phase 1 Completed
NCT01629615 2020-10-28
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT01610284 2020-08-25
BELLE-2
Novartis
Phase 3 Completed
NCT01737450 2019-06-24
PIK-ORL
Centre Leon Berard
Phase 2 Completed
NCT01741753 2019-02-05
BKM120+Abiraterone Acetate for Metastatic CRPC
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT01633060 2019-01-30
BELLE-3
Novartis
Phase 3 Terminated
NCT01790932 2019-01-23
BKM120 For Triple Negative Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01911325 2018-08-14
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
Novartis
Phase 1 Terminated
NCT01385293 2017-05-19
BKM120 in Metastatic Castration-resistant Prostate Cancer
Duke University
Phase 2 Terminated
NCT02452294 2017-05-03
BUMPER
University Hospital Tuebingen
Phase 2 Unknown
NCT01571024 2017-04-26
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT01572727 2017-03-09
BELLE-4
Novartis
Phase 2/3 Completed
NCT02035124 2016-02-11
Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel
SCRI Development Innovations, LLC
Phase 2 Withdrawn